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ABSTRACT
Objectives: Global Anticoagulant Registry in the
FIELD-Atrial Fibrillation (GARFIELD-AF) explored the
impact of gender, risk factors and anticoagulant (AC)
treatment on 1-year outcomes in patients with non-
valvular atrial fibrillation (NVAF).
Design: GARFIELD-AF is a prospective non-
interventional registry.
Setting: Investigator sites (n=1048) are representative
of the care settings/locations in each of the 35
countries.
Participants: Patients ≥18yrs with newly diagnosed
(≤6 weeks’ duration) NVAF and ≥1 investigator-
determined stroke risk factors.
Main outcome measures: Event rates per 100
person-years were estimated from the Poisson model
and HRs and 95% CIs calculated.
Results: Of 28 624 patients (women 44.4%; men
55.6%) enrolled, there were more elderly (≥75 years)
women (46.9%) than men (30.4%). All-cause mortality
rates per 100 person-years (95% CI) for women and
men were 4.48 (4.12 to 4.87) and 4.04 (3.74 to 4.38),
respectively, stroke/systemic embolism (SE) (1.62
(1.41 to 1.87) and 1.17 (1.01 to 1.36)) and major
bleeding (0.93 (0.78 to 1.13) and 0.79 (0.66 to 0.95)).
After adjustment for baseline risk factors in treated and
untreated patients, HRs (95% CI) for women (relative
to men) for stroke/SE rates were 1.3-fold higher in
women (HR 1.30 (1.04 to 1.63)), and similar for major
bleeding (1.13 (0.85 to 1.50)) and all-cause mortality
(1.05 (0.92 to 1.19)). Antithrombotic treatment
patterns in men and women were almost identical.
63.8% women and 62.9% men received AC±
antiplatelets. Relative to no AC treatment, the reduction
in stroke/SE rates with AC treatment was greater
(p=0.01) in men (HR 0.45 (0.33 to 0.61)) than women
0.77 (0.57 to 1.03). All-cause mortality reduction with
AC treatment was similar (women: 0.65 (0.54 to 0.77);
men: 0.57 (0.48 to 0.68)). The risk of major bleeding
when treated with AC versus no AC was 2.33 (1.41 to
3.84) in men and 1.86 (1.16 to 2.99) in women
(p value=0.53).
Conclusions: Women have a higher risk of stroke/SE
and the reduction in stroke/SE events rates with AC
treatment is less in women than in men.
Trial registration number: NCT01090362.
INTRODUCTION
Every year, ∼15 million people around the
world experience a stroke, and 5 million die
from their disease.1 Ischaemic stroke
accounts for the majority of these events,2
and patients with atrial ﬁbrillation (AF) are
up to ﬁve times more likely to experience a
stroke than patients without AF.3 4
Gender differences in the prevalence and
prognosis of patients with AF are widely
reported (mainly based on epidemiological
studies from Europe and North America).5–7
Strengths and limitations of this study
▪ Global Anticoagulant Registry in the FIELD-Atrial
Fibrillation (GARFIELD-AF) is the largest pro-
spective, ongoing, observational, multicentre,
prospective study of patients aged ≥18 years
with newly diagnosed NVAF and ≥1 investigator-
determined stroke risk factor(s).
▪ The GARFIELD-AF registry reflects ‘real-world’
care settings for unselected patients with non-
valvular AF globally.
▪ The interpretation of the differences in stroke/
systemic embolism events between men and
women is hampered by the lack of data on
dosing and persistence with AC treatment.
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These studies show that the age-adjusted prevalence of
AF is higher in men than women (596 per 100 000 in
men and 373 per 100 000 in women),5 but with greater
longevity, women make up the greater proportion
(60%) of those with AF who are over the age of 75
years.5 8 9 The prognosis for women with AF markedly
differs from men.10 Female gender independently
increases the risk of stroke,11–16 and women with AF
have a higher mortality rate, even after adjustment for
baseline comorbid conditions and treatment with antic-
oagulants (ACs).17 18 For this reason, female gender is a
recognised risk factor for stroke in the CHA2DS2-VASc
stroke risk stratiﬁcation scheme19 as used in inter-
national guidelines for stroke prevention in AF.20–23 The
reason for these disparities in prognosis between men
and women are not fully understood.
In this paper, we analysed the impact of gender and
gender-associated differences in risk factors and AC
treatment on 1-year outcomes in patients with newly
diagnosed non-valvular atrial ﬁbrillation (NVAF) based
on data from the Global Anticoagulant Registry in the
FIELD-Atrial Fibrillation (GARFIELD-AF).24
Previously, we have shown that the use of AC in NVAF
does not differ between men and women enrolled
in GARFIELD-AF, although many patients received
suboptimal thromboprophylaxis, with underuse in
moderate-to-high risk patients and overuse in low-risk
patients.25
MATERIALS AND METHODS
Study design and patients
GARFIELD-AF is an ongoing observational, multicentre,
prospective study24 of patients aged ≥18 years with newly
diagnosed (≤6 weeks’ duration) NVAF and ≥1
investigator-determined stroke risk factor(s). Risk factors
are determined by the investigators (a complete list of
investigators is given in the online supplementary
appendix) and are not prespeciﬁed in the protocol, nor
are they limited to the components of existing risk strati-
ﬁcation schemes. Patients with a transient reversible
cause of AF and those for whom follow-up to 2 years is
not envisaged or not possible are excluded from the
study. Sites were identiﬁed globally and on a national
level from hospital, community and anticoagulation
clinic settings to ensure proportional representation of
AF treating care settings in all countries (as previously
described24).
Study ethics
The central ethics committees and regulatory authorities
that provided approval are listed in the online
supplementary appendix. The registry is being con-
ducted in accordance with the principles of the
Declaration of Helsinki, local regulatory requirements
and the International Conference on Harmonisation–
Good Pharmacoepidemiological and Clinical Practice
guidelines. All patients provided written informed
consent.
Data collection
Data collected at enrolment included patient and clin-
ical characteristics, medical history, care setting at diag-
nosis, type of AF, symptoms and antithrombotic
treatment (vitamin K antagonists (VKAs), factor Xa inhi-
bitors and direct thrombin inhibitors). These data were
used to calculate the CHA2DS2-VASc score (Cardiac
failure, Hypertension, Age ≥75 (Doubled), Diabetes,
Stroke (Doubled)-Vascular disease, Age 65–74 and Sex
category (Female)), CHADS2 and HAS-BLED score
(Hypertension, Abnormal renal/liver function, Stroke,
Bleeding history or predisposition, Elderly (>65 years),
Drugs/alcohol concomitantly); data on labile
International Normalized Ratio (INR) was not collected
and so was not included in the HAS-BLED. Major bleed-
ing was deﬁned according to International Society on
Thrombosis and Haemostasis (ISTH) criteria.
The electronic case report form (eCRF) was designed
by Dendrite Clinical Systems (Henley-on-Thames, UK).
Oversight of operations and data management are being
managed by the sponsor and coordinating centre
(Thrombosis Research Institute, London,7 UK), with
support from Quintiles (Durham, NC, USA), The
University of Birmingham Department of Primary Care
Clinical Sciences (Birmingham, UK), Thrombosis
Research Group—Brigham and Women’s Hospital
(Boston, MA, USA) and AIXIAL (Paris, France).
Submitted data are examined for completeness and
accuracy by the coordinating centre (Thrombosis
Research Institute, London, UK). All quality control
measures are undertaken under the guidance of an
independent audit committee. Key protocol-driven ele-
ments of the audit include: frequent electronic data
monitoring; remote site monitoring by clinical research
associates including source document veriﬁcation of
20% of all cases as per the Monitoring Plan. Outcome
events were reported by investigators, after review of
patient notes and clinical records, and audited using a
combination of remote electronic monitoring and more
conventional onsite monitoring. Stroke/ systemic embol-
ism (SE), major bleeding and all-cause mortality rates
(per 100 persons-years) occurring during the ﬁrst year
of follow-up are calculated using the number of events
and the population at risk at the beginning of the
follow-up period. Only the ﬁrst occurrence of each
event was taken into account.
Statistical analysis
Continuous variables are presented as mean ±SD, and
categorical variables are presented as frequency and per-
centage. Patients with missing values were not removed
from the study (available case analysis). Occurrences of
major clinical outcomes are described using the person-
time event rate (per 100 person-years) and 95% CI. We
estimated person-year rates using a Poisson model, with
2 Camm AJ, et al. BMJ Open 2017;7:e014579. doi:10.1136/bmjopen-2016-014579
Open Access
the number of events as the dependent variable and the
log of time as an offset, that is, a covariate with a known
coefﬁcient of 1.
HRs and 95% CIs were calculated using a propor-
tional hazards Cox regression model after multiple
imputations by the Multiple Imputation by Chained
Equations (MICE) algorithm assuming that data are
missing at random. HRs were adjusted for: age group,
race, smoking, diabetes mellitus, hypertension, previous
stroke/systemic embolism, history of bleeding, cardiac
failure, vascular disease, moderate-to-severe renal
disease, AC treatment and type of AF. The proportional
hazards assumption was assessed visually using a plot of
the survivor function over time by gender. As the model
used to estimate the HRs includes interaction between
gender and risk factors, we carried out multiple imputa-
tions separately for men and women to allow the associa-
tions between risk factors and the clinical outcomes to
differ according to gender. The model for multiple
imputation included baseline characteristics (age, race,
type of AF, history of bleeding, diabetes, hypertension,
previous stroke, congestive heart failure, vascular
disease, AC treatment and hypercholesterolaemia) and
clinical endpoints (indicators of death, stroke/SE, major
bleeding). We imputed ﬁve complete data sets and com-
pared the distribution of the completed and observed
data for baseline characteristics to check for any anomal-
ies. Three models were ﬁtted for each clinical outcome:
(1) a model estimating the main effect of gender and
risk factors. This model does not include interactions
between gender and risk factors. The effect of risk
factors on clinical outcome is assumed to be the same
for men and women; (2) a model with interactions
between gender and each risk factor. Using this model,
the effect of each risk factor on clinical outcomes separ-
ately for men and women were estimated and (3) a
model with signiﬁcant interactions between gender and
risk factors. This model includes only signiﬁcant interac-
tions tested in model 2. Model 1 is presented in online
supplementary ﬁgure S1 and as online supplementary
data, model 2 is presented in main text of the manu-
script, whereas model 3 is presented as online
supplementary data. All data analyses were performed at
the Thrombosis Research Institute using SAS V.9.4 (SAS
Institute, Cary, NC, USA) and Stata Statistical Software:
Release 14 (StataCorp, College Station, TX, USA).
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in
developing plans for design or implementation of the
study. No patients were asked to advice on interpretation
or writing up of results. There are no plans to dissemin-
ate the results of the research to study participants or
the relevant patient community. However, we are now
including the Anti-Clot Treatment Scale (ACT) as part
of the patient assessment in cohort 5 in order to provide
a measure of patient-reported outcomes.
RESULTS
Baseline characteristics
A total of 28 624 patients (women 12 709 (44.4%) and
men 15 915 (55.6%)) with newly diagnosed NVAF were
enrolled into the GARFIELD-AF registry at 1048 sites in
35 countries between March, 2010 and October, 2014.
The data were extracted from the study database on 3rd
August, 2015. Baseline characteristics are presented by
gender in table 1. The mean (SD) age of women and
men were 72.4±10.4 years and 67.6±11.7 years, respect-
ively; a greater proportion of women than men (46.9%
vs 30.4%) were 75 years or older.
Lifestyle risk factors measured at baseline showed that
more men than women were current or ex-smokers
(women 15.9%; men 50.1%) or heavy drinkers (women
0.4%; men 4.2%), with a greater proportion of women
being abstinent (men 39.2%; women 73.0%).
A slightly higher proportion of women compared with
men were diagnosed with paroxysmal AF (women
29.1%; men 25.1%). Women were slightly more likely to
have a history of hypertension or raised blood pressure
≥140/90 mm Hg (women 84.8%; men 79.5%) (table 1).
Vascular disease and history of prior coronary artery
bypass graft and heart failure (left ventricular ejection
fraction <40%) at the time of diagnosis of NVAF were
more common in men.
At baseline, mean HAS-BLED scores were 1.5±0.9 and
1.4±0.9, mean (±SD) CHADS2 scores were 2.0±1.1 and 1.8
±1.1 and mean CHA2DS2-VASc scores were 4.0±1.4 and 2.6
±1.5 for women and men, respectively. Overall, 97.0% of
women and 76.5% of men had a CHA2DS2-VASc score ≥2.
Treatment patterns
The pattern of antithrombotic treatment in men and
women was almost identical (ﬁgure 1). At the time of
diagnosis, 63.8% women and 62.9% men received AC
with or without antiplatelet (AP) therapy; most patients
(women 46.8%; men 46.0%) were prescribed VKAs—
with or without AP treatment, and the remainder
(women 17.1%; men 16.9%) received non-VKA oral AC
(NOACs). Approximately one-quarter of patients
(women 23.9%; men 24.9%) received AP treatment
only. The proportion of women and men who received
neither AC treatment nor AP treatment was 12.3% and
12.2%, respectively. Of patients with a low risk of stroke,
39.7% of women (CHA2DS2-VASc score=1) and 43.3% of
men (CHA2DS2-VASc score=0) received AC treatment.
Of patients with a high risk of stroke (CHA2DS2-VASc
score ≥2), 35.2% of women and 33.3% of men did not
receive AC treatment. A minority of women (n=16) used
hormone replacement therapy (HRT) (at least two pre-
scriptions at any point prior to a diagnosis of AF) and
were similarly distributed in the group of anticoagulated
(n=7) and non-anticoagulated patients (n=9).
Clinical outcomes over 1 year
Figure 2 displays unadjusted event rates per 100 person-
years and the adjusted HRs for women (with reference
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Table 1 Baseline characteristics of women and men with newly diagnosed atrial fibrillation: the GARFIELD-AF registry
Variable* Men (n=15 915) Women (n=12 709)
Age, mean (SD), years 67.6±11.7 72.4±10.4
Age group (years), n (%)
<65 years 5847 (36.7) 2670 (21.0)
65–74 years 5235 (32.9) 4082 (32.1)
≥75 years 4832 (30.4) 5957 (46.9)
Race, n %†
Caucasian/Hispanic/Latino 10 994 (69.1) 9240 (72.7)
Asian 4228 (26.6) 2928 (23.0)
Body mass index, mean (SD), kg/m2 27.7±5.1 27.9±6.2
LVEF category, n (%)
<40% 1226 (13.1) 4378 (6.2)
≥40% 8098 (86.9) 6609 (93.8)
Type of AF diagnosed, n (%)
Permanent 2052 (12.9) 15 834 (12.5)
Persistent 2585 (16.2) 1782 (14.0)
Paroxysmal 3988 (25.1) 3692 (29.1)
New (unclassified) 7289 (45.8) 5651 (44.5)
Medical history, n (%)
Congestive heart failure, NYHA Class, n (%)
I 632 (21.2) 416 (17.0)
II 1408 (47.3) 1241 (50.7)
III 792 (26.6) 682 (27.8)
IV 146 (4.9) 111 (4.5)
Carotid occlusive disease, n (%) 505 (3.2) 361 (2.9)
PE or DVT, n (%) 362 (2.3) 403 (3.2)
Systemic embolism 100 (0.6) 94 (0.7)
Coronary artery bypass graft, n (%) 689 (4.4) 164 (1.3)
Moderate to severe CKD, n (%) 1458 (9.2) 1511 (11.9)
Stroke/TIA, n (%) 1839 (11.6) 1583 (12.5)
Stroke, n (%) 1243 (7.8) 1013 (8.0)
History of bleeding, n (%) 469 (3.0) 311 (2.5)
Blood pressure, mm Hg
Systolic blood pressure, mm Hg, mean (SD) 132.8 (±19.3) 135.0 (±20.7)
Diastolic blood pressure, mm Hg, mean (SD) 80.1 (±12.8) 79.8 (±13.0)
Blood pressure ≥140/90 mm Hg, n (%) 4037 (27.2) 3741 (31.5)
History of hypertension, n (%) 11 945 (75.2) 10 212 (80.5)
History of hypertension or raised blood pressure ≥140/90 mm Hg, n (%) 12 634 (79.5) 10 773 (84.8)
Hypercholesterolaemia, n (%) 6232 (39.9) 5276 (42.3)
Diabetes mellitus, n (%) 3479 (21.9) 2728 (21.5)
Vascular disease‡, n (%) 2820 (17.7) 1508 (11.9)
CHA2DS2-VASc score
Mean (SD) 2.6 (1.5) 4.0 (1.4)
0, n (%) 676 (4.4) _
1, n (%) 2966 (19.1) 370 (3.0)
≥2, n (%) 11 857 (76.5) 12 082 (97.0)
Mean HAS-BLED score (SD) 1.4 (0.9) 1.5 (0.9)
Heavy alcohol consumption, n (%) 565 (4.2) 40 (0.4)
Current/previous smoker, n (%) 7210 (50.1%) 1850 (15.9%)
*Missing patients from analyses: Number of patients (men, women) with missing values: age (0,0), race (429 346), body mass index (3231,
2858), blood pressure (1051, 830), LVEF (6591, women), type of AF diagnosed (1, 1), congestive heart failure, NYHA class (228, 189),
carotid occlusive disease (117, 87), PE or DVT (46, 47), systemic embolism (48, 43), coronary artery bypass graft (350, 208), moderate to
severe CKD (2, 1), stroke (33, 30), history of bleeding (37, 38), hypertension (22, 23), hypercholesterolaemia (300, 248), diabetes mellitus
(1, 1) vascular disease (1, 1), CHA2DS2-VASc score (416, 257), HAS-BLED score (5230, 3947), alcohol consumption (2516, 1893) smoking
habits (1529, 1052).
†346 women and 427 men were unwilling to declare their race or their race was not recorded.
‡Peripheral artery disease or coronary artery disease with a history of acute coronary syndromes.
AF, atrial fibrillation; CKD, chronic kidney disease; CHA2DS2-VASc score, Cardiac failure, Hypertension, Age ≥75 (Doubled), Diabetes, Stroke
(Doubled)-Vascular disease, Age 65–74 and Gender category (Female); DVT, deep venous thrombosis; HAS-BLED, Hypertension
(uncontrolled, >160 mm Hg systolic), Abnormal renal/liver function, Stroke, Bleeding history or predisposition (anaemia), Elderly (>65) and
Drugs/alcohol concomitantly (antiplatelet agents, non-steroidal anti-inflammatory drug); LVEF, left ventricular erection fraction; NYHA, New
York Heart Association; PE, Pulmonary embolism; TIA, Transient ischaemic attack.
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to men). Unadjusted event rates per 100 person-years
(95% CI) in women and men, respectively, were: stroke/SE
(1.62 (1.41 to 1.87) and 1.17 (1.01 to 1.36)), major
bleeding (0.93 (0.78 to 1.13) and 0.79 (0.66 to 0.95))
and all-cause mortality (4.48 (4.12 to 4.87) and 4.04
(3.74 to 4.38)). When HRs (95% CI) were adjusted for
baseline risk factors (as deﬁned in ﬁgure 2), stroke/SE
were 1.3-fold higher for women compared with men
(HR 1.30 (1.04 to 1.63)), whereas the HR for major
bleeding was 1.13 (0.85 to 1.50) and for all-cause mortal-
ity, the HR was 1.05 (0.92 to 1.19).
Multivariate Cox regression analysis of HRs adjusted for
risk factors by gender
Adjusted HRs estimated using model 1 describe the
effect of gender on clinical outcomes (ﬁgure 2 and
online supplementary tables S1–S3). Model 2 with HRs
adjusted for risk factors by gender for all clinical out-
comes is presented in ﬁgure 3 and in table 2. Additional
information from the statistical models 1 and 3 and
missing values are presented in the appendix (see
online supplementary tables S1–S4, respectively). Our
results are robust when removing non-signiﬁcant interac-
tions (model 3), but for descriptive purposes, we present
the results from model 2, which includes 24 852
Figure 1 Antithrombotic treatment at diagnosis. AP,
antiplatelet; NOAC, non-vitamin K antagonist oral
anticoagulants; VKA, vitamin K antagonists.
Figure 2 Kaplan-Meir curves for men and women for all-cause mortality, stroke/SE and major bleeding during the first year of
follow-up. SE, systemic embolism.
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complete cases and 3772 patients with at least one
imputed value (table 2).
The analyses show that the risk of all clinical end-
points increases with advancing age in men and women.
Men from the age of 65 years have an elevated risk of all
endpoints compared with younger men with AF
(<65 years). In contrast, the stroke risk is elevated in
women only from the age of 70 onwards compared with
women with AF (<65 years).
Patients with NVAF from Asia have a lower risk of all-
cause mortality and major bleeding (but not stroke)
compared with patients of other ethnicities (Caucasian,
Hispanic or Latino); the risk of events is similar across
ethnicities of the same gender (ﬁgure 3 and table 2).
Current smoking is a risk factor for all events and ces-
sation of smoking was associated with reduced risk of
events (relative to current smokers) in both genders.
Diabetes mellitus carried a similar risk for all-cause mor-
tality in men and women with NVAF. Hypertension (pre-
dominantly characterised by a history of hypertension)
was associated with a reduction in the risk of 1-year all-
cause mortality in men and women and was an equally
important risk factor for stroke in men and women.
Hypertension was also associated with an increased risk
of major bleeding in women, but not men, but this
gender difference was not statistically signiﬁcant
(women: HR 1.22 (95% CI 0.66 to 2.24); men: HR 0.77
(95% CI 0.50 to 1.20); p=0.23; table 2). An equally
important risk factor for all-cause mortality in women
and men with AF was congestive heart failure (HR >2).
A history of bleeding was associated with a higher risk of
all events, but with a signiﬁcantly elevated risk of all-
cause mortality in women compared with men (women:
HR 2.28 (95% CI 1.64 to 3.17), men HR 1.37 (95% CI
0.98 to 1.91) p=0.03; table 2).
Severe renal disease was associated in an elevated risk
of all events in both genders. The risk of stroke in
patients with vascular disease appeared to be elevated in
women but not men (women: HR 1.33 (0.92 to 1.95);
men: HR 1.01 (0.70 to 1.46); although the difference was
not statistically signiﬁcant p=0.30) (ﬁgure 3 and table 2).
In women and men, prior stroke/transient ischaemic
attack/SE was a risk factor for a subsequent stroke event
and this risk was signiﬁcantly lower in women than in
men (women: 1.69 (1.20 to 2.38); men: 2.69 (1.92 to
3.77); p=0.06).
Compared with no AC treatment, AC treatment
lowered the risk of stroke/SE to a greater extent in men
Figure 3 Forest plot of HRs for
1-year clinical outcomes
according to risk factors in men
and women (Square to men and
Circle to women). AC,
anticoagulation; AF, atrial
fibrillation; SE, systemic
embolism; TIA, transient
ischaemic attack. Adjustment
factors for HRs: age group, race,
smoking, diabetes mellitus,
hypertension, previous stroke/TIA/
systemic embolism, history of
bleeding, congestive heart failure
(CHF), vascular disease,
moderate-to-severe renal
disease, anticoagulant treatment
and type of atrial fibrillation.
Hypertension was defined as a
documented history of
hypertension or blood pressure
>140/90 mm Hg. Results of
Model 2.
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Table 2 Adjusted HRs (95% CIs) according to risk factors by gender and p values for the interaction between gender and risk factors
Risk factor
All-cause mortality Stroke/SE Major bleeding
Women Men Women Men Women Men
Age p=0.71 p=0.17 p=0.64
65–69 years (ref: <65) 1.23 (0.78 to 2.67) 1.96 (1.44 to 2.67) 0.93 (0.50 to 1.75) 2.39 (1.50 to 3.81) 1.13 (0.47 to 2.73) 1.48 (0.77 to 2.84)
70–74 years (ref: <65) 1.86 (1.27 to 2.74) 2.28 (1.71 to 3.05) 1.38 (0.82 to 2.33) 2.45 (1.55 to 3.87) 1.78 (0.84 to 3.78) 2.39 (1.35 to 4.24)
≥75 years (ref: <65) 3.72 (2.69 to 5.15) 4.17 (3.27 to 5.32) 1.89 (1.21 to 2.94) 2.05 (1.34 to 3.16) 2.44 (1.26 to 4.72) 2.37 (1.40 to 4.01)
Race p=0.33 p=0.89 p=0.51
Asian (ref: Caucasian/Hispano/Latino) 0.87 (0.69 to 1.10) 0.70 (0.56 to 0.88) 0.99 (0.60 to 1.42) 0.93 (0.65 to 1.32) 0.52 (0.27 to 0.99) 0.69 (0.41 to 1.17)
Smoking p=0.61 p=0.98 p=0.76
Ex-smoker (ref: no) 1.42 (1.11 to 1.84) 1.24 (1.04 to 1.48) 0.92 (0.54 to 1.58) 0.96 (0.67 to 1.37) 1.13 (0.63 to 2.01) 1.30 (0.86 to 1.97)
Current smoker (ref: no) 1.59 (1.06 to 2.40) 1.37 (1.06 to 1.78) 1.60 (0.85 to 3.03) 1.51 (0.99 to 2.31) 1.96 (0.93 to 4.12) 1.55 (0.84 to 2.70)
Diabetes mellitus p=0.86 p=0.63 p=0.21
Yes (ref: no) 1.24 (1.02 to 1.51) 1.21 (1.01 to 1.46) 1.04 (0.74 to 1.46) 1.18 (0.83 to 1.66) 0.80 (0.50 to 1.30) 1.20 (0.80 to 1.81)
Hypertension p=0.73 p=0.90 p=0.23
Yes (ref: no) 0.75 (0.60 to 0.95) 0.79 (0.65 to 0.97) 1.19 (0.76 to 1.85) 1.15 (0.77 to 1.70) 1.22 (0.66 to 2.24) 0.77 (0.50 to 1.20)
Stroke/TIA/SE p=0.88 p=0.06 p=0.27
Yes (ref: no) 1.35 (1.09 to 1.68) 1.38 (1.13 to 1.70) 1.69 (1.20 to 2.38) 2.69 (1.92 to 3.77) 1.38 (0.86 to 2.22) 0.92 (0.54 to 1.57)
History of bleeding p=0.03 p=0.40 p=0.72
Yes (ref: no) 2.28 (1.64 to 3.17) 1.37 (0.98 to 1.91) 1.85 (1.00 to 3.44) 1.25 (0.63 to 2.46) 1.26 (0.46 to 3.47) 1.61 (0.70 to 3.69)
Congestive heart failure p=0.72 p=0.57 p=0.68
Yes (ref: no) 2.25 (1.89 to 2.68) 2.35 (2.00 to 2.77) 1.18 (0.86 to 1.61) 1.34 (0.97 to 1.86) 0.91 (0.58 to 1.42) 1.03 (0.69 to 1.55)
Vascular disease p=0.29 p=0.30 p=0.70
Yes (ref: no) 1.50 (1.21 to 1.85) 1.29 (1.08 to 1.55) 1.33 (0.92 to 1.95) 1.01 (0.70 to 1.46) 1.33 (0.80 to 2.21) 1.17 (0.76 to 1.80)
Severe renal disease p=0.25 p=0.36 p=0.85
grade III-IV-V (ref: I, II, no, unknown) 1.69 (1.38 to 2.07) 1.99 (1.64 to 2.42) 1.70 (1.19 to 2.42) 1.30 (0.83 to 2.04) 1.97 (1.27 to 3.07) 2.10 (1.33 to 3.30)
AC treatment p=0.28 p=0.01 p=0.53
Yes (ref: no) 0.65 (0.54 to 0.77) 0.57 (0.48 to 0.67) 0.77 (0.57 to 1.03) 0.45 (0.33 to 0.61) 1.86 (1.16 to 2.99) 2.33 (1.41 to 3.84)
Type of AF p=0.49 p=0.96 p=0.27
Permanent AF (ref: no) 1.32 (0.98 to 1.78) 1.22 (0.91 to 1.62) 1.19 (0.74 to 1.91) 1.22 (0.74 to 2.02) 0.60 (0.29 to 1.23) 1.57 (0.84 to 2.96)
Persistent AF (ref: no) 1.47 (1.10 to 1.97) 1.11 (0.83 to 1.49) 1.44 (0.92 to 2.23) 1.25 (0.77 to 2.02) 0.93 (0.49 to 1.76) 1.33 (0.70 to 2.51)
New AF (ref: no) 1.51 (1.20 to 1.89) 1.49 (1.20 to 1.86) 1.05 (0.73 to 1.49) 1.07 (0.73 to 1.56) 1.11 (0.71 to 1.73) 1.51 (0.89 to 2.54)
AC, anticoagulants; AF, atrial fibrillation; ref, reference; SE, systemic embolism; TIA, transient ischaemic disease. Results of Model 2.
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than women (women: HR 0.77 (95% CI 0.57 to 1.03);
men: HR 0.45 (95% CI 0.33 to 0.61)), and this inter-
action was signiﬁcant (p=0.01). The reduction in all-
cause mortality with AC treatment was similar in both
genders (women: HR 0.65 (95% CI 0.54 to 0.77); men:
HR 0.57 (95% CI 0.48 to 0.68)). Men, however, had a
higher risk of major bleeding when treated with ACs
(HR 2.33 (95% CI 1.41 to 3.84)) compared with women
(HR 1.86 (95% CI 1.16 to 2.99)); although this inter-
action was not signiﬁcant.
DISCUSSION
The GARFIELD-AF study found that women had a
higher risk of stroke/SE than men even after adjustment
of risk factors (congestive heart failure, age, hypertension,
diabetes mellitus, prior stroke/SE, vascular disease and
history of bleeding). The event rates from GARFIELD-AF
correspond to the results from two recent meta-analyses
of pooled data from the literature which determined that
the unadjusted risk of stroke in women, relative to men,
was 1.47 (95% CI 1.18 to 1.83)26 and the adjusted risk
was 1.31 (1.18 to 1.46).27
The impact of gender on all-cause mortality in
patients with AF is inconsistently reported in the litera-
ture.26 The results from the GARFIELD-AF study of
>28 000 patients found that the unadjusted rate of all-
cause mortality per 100 person-years was only slightly ele-
vated in women (4.48) compared with men (4.04). After
adjustment for baseline risk factors, all-cause mortality
in women, relative to men, was similar.
Our analysis highlights differences in patient
characteristics between men and women presenting with
NVAF. One of the most notable differences is age. At the
time of enrolment in the GARFIELD-AF registry, the
mean age of patients with newly diagnosed NVAF was
lower for men than women (68 vs 72 years). This result
is comparable with age distribution between women and
men which has been reported in other studies of
patients with AF such as the Monitoring and Observing
the Value of Exercise (MOVE) study (67 vs 71 years),28
RAte Control versus Electrical cardioversion for persist-
ent atrial ﬁbrillation (RACE) (67 vs 71 years)29 and the
Euro Heart Survey (ESC) (64 vs 70 years).30
Of note, there was a greater proportion of women
than men who were 75 years or older at the time of diag-
nosis of NVAF which is in accordance with other
studies.8 31 There was also a trend toward a greater
prevalence of comorbid vascular disease in men (than
women) and comorbid hypertension in women.
Otherwise, the prevalence of other risk factors for stroke
(diabetes, prior stroke/SE) is similar in men and
women. The Framingham study found that gender dif-
ferences in blood pressure gradually narrow with age.
Eventually, women develop higher blood pressure than
men (beyond age 60 years) with the accelerated onset of
arterial stiffening beyond menopause (especially in
women with a history of hypertension).32
As reﬂected in the mean CHA2DS2-VASc scores (4.0±1.4
and 2.6±1.5 for women and men) beyond the impact of
gender, there are only small differences in the risk factors
for stroke in men and women with newly diagnosed
NVAF. This difference can be explained by the greater age
of female patients.33 In GARFIELD-AF, we found that only
prior stroke and AC treatment were signiﬁcantly associated
with gender-related differences in stroke event rates after
adjustment for baseline risk factors.
It is recognised that the risk of thromboembolism
increases with advancing age in patients above 65 years.34
Similar to the Danish registry, which calculated stroke
rates according to sex and age, we found that the risk of
stroke tended to be elevated in women only from the age
of 70 years and in men from 65 years onwards compared
with patients of the same gender with AF (<65 years).
However, the Loire Valley AF study reported that in rela-
tively young patients with AF (<65 years), the risk of
stroke/thromboembolism can be independently
increased by the presence of heart failure, prior stroke or
vascular disease.31 In GARFIELD-AF, even though men
were younger than women at the time of AF diagnosis
(mean age for men: 67.6 years), they were more likely to
present with vascular disease, be current/past smokers
(and/or heavy drinkers) and as likely to have had a
history of heart failure (New York Heart Association
(NYHA) class III–IV) or prior stroke/transient ischaemic
attack as older women. We found that there was an unex-
pectedly higher risk of recurrent stroke in men than in
women in the year following the diagnosis of AF.
The effects of AC treatment on stroke prevention were
signiﬁcantly greater in men than in women but were
also associated with greater risk of bleeding. We found
that the pattern of AC treatment did not differ markedly
in men and women or among the minority of women
(n=19) who had received HRT. Nevertheless, subtle dif-
ferences in prescribing patterns by gender are evident.
For example, AC treatment in combination with AP
therapy was more frequently prescribed for men than
women, which may have contributed to the increased
risk of bleeding with AC treatment in men. Other pub-
lished studies have shown that gender and age also inﬂu-
ence dose. For example, women require less warfarin to
maintain a therapeutic INR than men at an equivalent
age and dosing reduces proportionally with increasing
age.35 The greater risk of bleeding in men may be
explained by more aggressive AC dosing in men (relative
to women). Conversely, the lower impact of AC treat-
ment on stroke rates in women may be due to poorer
anticoagulation control as determined by Atrial
Fibrillation Follow-up Investigation of Rhythm
Management (AFFIRM).36 In this study, women were
more likely to be outside the time in therapeutic range
(TTR) and have subtherapeutic INRs. However, the
GARFIELD-AF showed that the mean (SD) TTR is
similar in men, 55.6 (27.1) and women, 55.2 (26.9).
An important consideration in women is the impact of
age on prescribing practice and adherence to
8 Camm AJ, et al. BMJ Open 2017;7:e014579. doi:10.1136/bmjopen-2016-014579
Open Access
medication, since a higher proportion of women than
men were elderly (75 years or older). There is also evi-
dence (from a recent meta-analysis of randomised con-
trolled studies reporting annualised event rates) that
women with AF have a signiﬁcantly greater residual risk
of stroke/SE (compared with men) when treated using
warfarin. The AFFIRM study, for example, showed that
women who had a comparably high TTR (>66%) still
had signiﬁcantly more ischaemic strokes.36 However, this
gender difference is not observed in randomised con-
trolled trials (RCTs) with NOACs.15 The same
meta-analysis of RCTs also found that NOAC agents are
associated with signiﬁcantly more major bleeding in men
than women. The reason for these gender differences in
controlled clinical trials is not completely understood.15
CONCLUSIONS
Across the models, we found that only prior stroke and
AC treatment were signiﬁcantly associated with gender-
related differences in stroke event rates after adjustment
for baseline risk factors. The increased beneﬁt of AC
treatment on stroke prevention in men, relative to
women, is not fully understood, but suggests that women
may be less well anticoagulated.
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